title: [Basal cell carcinoma surgery].
abstract: Basal cell carcinoma (BCC) is the most common type of cancer in humans. The lifetime risk of developing BCC is 30%. The scope of the treatment is total eradication of the tumour followed by preservation of functionality and optimal cosmetic results. The risk of recurrence after treatment is highest in the tumours with aggressive growth patterns, in tumours located in the facial H-zone and in recurrent tumours. The optimal treatment of high-risk BCCs is surgical excision or radiotherapy. Low-risk tumours may be treated with cryotherapy, curettage, photodynamic therapy or topical agents.
authors.affiliation: glud.martin@gmail.com.
authors.forename: Martin
authors.initials: M
authors.lastname: Glud
authors.forename: Silje Haukali
authors.initials: SH
authors.lastname: Omland
authors.forename: Robert
authors.initials: R
authors.lastname: Gniadecki
mesh_terms: D002280:Basal Cell Carcinoma / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D009362:Neoplasm Metastasis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*